| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12672-018-0353-6 |
| P698 | PubMed publication ID | 30565014 |
| P50 | author | Lenore K Beitel | Q42961532 |
| Miltiadis Paliouras | Q90626759 | ||
| P2093 | author name string | Enrico O Purisima | |
| Mark Trifiro | |||
| Shafinaz Chowdhury | |||
| Rose Lumbroso | |||
| P2860 | cites work | A stapled BID BH3 helix directly binds and activates BAX | Q24307663 |
| The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor | Q24316455 | ||
| Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix | Q24537504 | ||
| Recognition and accommodation at the androgen receptor coactivator binding interface | Q24799399 | ||
| Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures | Q27621576 | ||
| Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions | Q27642107 | ||
| Solution Structure of a Hydrocarbon Stapled Peptide Inhibitor in Complex with Monomeric C-terminal Domain of HIV-1 Capsid | Q27650342 | ||
| Integrative clinical genomics of advanced prostate cancer | Q27853170 | ||
| Global cancer statistics, 2012 | Q27860501 | ||
| The Amber biomolecular simulation programs | Q27860745 | ||
| A signature motif in transcriptional co-activators mediates binding to nuclear receptors | Q27860938 | ||
| Comparison of multiple Amber force fields and development of improved protein backbone parameters | Q27861040 | ||
| Discordant measures of androgen-binding kinetics in two mutant androgen receptors causing mild or partial androgen insensitivity, respectively | Q28137601 | ||
| Principles for modulation of the nuclear receptor superfamily | Q28291197 | ||
| Characterization of steroid receptors in human prostate using mibolerone | Q28301843 | ||
| Development and testing of a general amber force field | Q29547642 | ||
| Contemporary strategies for the stabilization of peptides in the alpha-helical conformation | Q33369664 | ||
| Selective oestrogen receptor modulation: molecular pharmacology for the millennium | Q33837314 | ||
| Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications | Q33922947 | ||
| Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer | Q33944430 | ||
| A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. | Q33955634 | ||
| Radical prostatectomy or watchful waiting in early prostate cancer | Q33985455 | ||
| Binding of ligands and activation of transcription by nuclear receptors. | Q34243256 | ||
| Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness | Q34495620 | ||
| Proteomic-coupled-network analysis of T877A-androgen receptor interactomes can predict clinical prostate cancer outcomes between White (non-Hispanic) and African-American groups | Q34542337 | ||
| Activation of nuclear receptors: a perspective from structural genomics | Q35169554 | ||
| Androgen receptor gene polymorphisms and alterations in prostate cancer: of humanized mice and men. | Q35281575 | ||
| Radical prostatectomy versus observation for localized prostate cancer | Q36194308 | ||
| Population-based study of long-term functional outcomes after prostate cancer treatment. | Q36260481 | ||
| Molecular modelling of the androgen receptor axis: rational basis for androgen receptor intervention in androgen-independent prostate cancer | Q36344198 | ||
| Protein transduction: cell penetrating peptides and their therapeutic applications | Q36486158 | ||
| Regulators of Androgen Action Resource: a one-stop shop for the comprehensive study of androgen receptor action | Q36578330 | ||
| Nonsteroidal bivalent estrogen ligands: an application of the bivalent concept to the estrogen receptor | Q36781304 | ||
| Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial | Q36841565 | ||
| Androgen receptor coactivators and prostate cancer. | Q37170528 | ||
| Androgen deprivation therapy: past, present and future | Q38016530 | ||
| Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, | Q38370247 | ||
| The hallmarks of castration-resistant prostate cancers | Q38485197 | ||
| Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic | Q38859753 | ||
| An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). | Q39127743 | ||
| Conformational analysis of bivalent estrogen receptor ligands: from intramolecular to intermolecular binding | Q39453226 | ||
| Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival | Q40287967 | ||
| Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. | Q40421840 | ||
| High incidence of urological complications in men dying from prostate cancer | Q40718493 | ||
| Androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase | Q40841145 | ||
| Bivalent inhibition of beta-tryptase: distance scan of neighboring subunits by dibasic inhibitors | Q43962814 | ||
| Isolation and characterization of androgen receptor mutant, AR(M749L), with hypersensitivity to 17-beta estradiol treatment | Q44260466 | ||
| Syntheses and ligand-binding studies of 1 alpha- and 17 alpha-aminoalkyl dihydrotestosterone derivatives to human sex hormone-binding globulin | Q44574899 | ||
| Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer | Q44787047 | ||
| PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer | Q45144596 | ||
| Positron tomographic assessment of androgen receptors in prostatic carcinoma | Q45279143 | ||
| The interaction of human tryptase-beta with small molecule inhibitors provides new insights into the unusual functional instability and quaternary structure of the protease | Q45286964 | ||
| Disruption of gene expression and induction of apoptosis in prostate cancer cells by a DNA-damaging agent tethered to an androgen receptor ligand | Q46614980 | ||
| Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions | Q46635702 | ||
| Secondary structure based analysis and classification of biological interfaces: identification of binding motifs in protein-protein interactions | Q48400543 | ||
| Androgen receptor outwits prostate cancer drugs. | Q53907010 | ||
| Prostate cancer | Q57121731 | ||
| Nonpolar interactions of thrombin S' subsites with its bivalent inhibitor: methyl scan of the inhibitor linker | Q73838664 | ||
| Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide | Q79733375 | ||
| Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance | Q80961151 | ||
| Synthesis of all-hydrocarbon stapled α-helical peptides by ring-closing olefin metathesis | Q84261511 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 24-35 | |
| P577 | publication date | 2018-12-18 | |
| P1433 | published in | Hormones and Cancer | Q15716573 |
| P1476 | title | A Targeted Bivalent Androgen Receptor Binding Compound for Prostate Cancer Therapy | |
| P478 | volume | 10 |
Search more.